Steve Andrzejewski Appointed Corporate Head of Commercial Operations
BRISTOL, Tenn., May 27 /PRNewswire-FirstCall/ -- King Pharmaceuticals,
Inc. (NYSE: KG), announced today that it is establishing sales and marketing
operations in Princeton, New Jersey, to further strengthen the Company's well-
established sales and marketing capabilities. The Company's new site in New
Jersey will serve as a base for King's sales and marketing operations.
Brian A. Markison, acting President and Chief Executive Officer of King,
stated, "For the purpose of further enhancing our ability to continue King's
record of growth and to enable the Company to continue recruiting top sales
and marketing talent, we are establishing a presence in the geographic heart
of the U.S. pharmaceutical industry, which is in New Jersey. We look forward
to ramping up sales and marketing operations in New Jersey and taking
advantage of the benefits afforded by having a presence there."
King also announced that Steve Andrzejewski has joined the Company as
Corporate Head of Commercial Operations. Mr. Markison commented, "I am
pleased to announce the addition of Steve Andrzejewski as Corporate Head of
Commercial Operations, with responsibility for all our sales, marketing and
managed care activities. He comes to King with a long and distinguished
background in the pharmaceutical industry, including experience in a range of
areas such as managed care development, market research, strategic planning,
and the licensing, development, branding and launch of new products, most
notably Claritin(R). His initiative, expertise and leadership are valuable
additions to King's commercial team, and I look forward to his contributions
to our Company's future success."
Mr. Andrzejewski joins King with over 16 years of experience in the
pharmaceutical industry. Prior to joining King, Mr. Andrzejewski served as
Senior Vice President of Commercial Business for Endo Pharmaceuticals, and
Vice President of New Products and Vice President of Marketing for all
respiratory and anti-infective products at Schering-Plough Corporation. He
holds a bachelor's degree in Psychology from Hamilton College, and a Master of
Business Administration in Finance and International Business from New York
University's Stern School of Business.
King, headquartered in Bristol, Tennessee, is a vertically integrated
branded pharmaceutical company. King, an S&P 500 Index company, seeks to
capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and acquisitions, of
novel branded prescription pharmaceutical products in attractive markets and
the strategic acquisition of branded products that can benefit from focused
promotion and marketing and product life-cycle management.
This release contains forward-looking statements which reflect
management's current views of future events and operations, including, but not
limited to, statements pertaining to the Company's plan to establish the base
of operations for the Company's sales and marketing forces in New Jersey and
thereby enhance the Company's ability to continue King's record of growth and
recruit top sales and marketing talent. These forward-looking statements
involve certain significant risks and uncertainties, and actual results may
differ materially from the forward-looking statements. Some important factors
that may cause results to differ include: dependence on whether King
successfully establishes the base of operation for its sales and marketing
forces in New Jersey; and dependence on whether the establishment of New
Jersey as the base of operations for the Company's sales and marketing forces
enhances the Company's ability to continue its record of growth and continue
recruiting top sales and marketing talent. Other important factors that may
cause actual results to differ materially from the forward-looking statements
are discussed in the "Risk Factors" section and other sections of King's Form
10-K for the year ended December 31, 2003 and Form 10-Q for the first quarter
ended March 31, 2004, which are on file with the U.S. Securities and Exchange
Commission. King does not undertake to publicly update or revise any of its
forward-looking statements even if experience or future changes show that the
indicated results or events will not be realized.
SOURCE King Pharmaceuticals, Inc.
 back to top
Related links:
http://www.kingpharm.com
Company News On-Call:
http://www.prnewswire.com/comp/120319.html
CONTACT:
James E. Green, Executive Vice President,
Corporate Affairs, +1-423-989-8125, or Patrick J. O'Brien,
Director, Investor Relations, +1-423-989-7080, both of King
Pharmaceuticals, Inc.
|
